Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, mitoxantrone, Asparaginase, prednisone, thioguanine, vincristine, radiation therapy, allopurinol, bactrim
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 64 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
78
States / cities
Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more
Conditions
Gout
Interventions
Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
52
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more
Completed Phase 2 Interventional Results available

Intravenous Allopurinol in Heart Failure

NCT00181155
Conditions
Congestive Heart Failure
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension
Interventions
Losartan, Allopurinol, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 4 Interventional Results available

Allopurinol Add-on Treatment for Refractory Mania

NCT00643123
Conditions
Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278
Conditions
Chronic Gout, Hyperuricemia
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Mountain View, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Conditions
Gout
Interventions
Febuxostat, Allopurinol
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
258
States / cities
Birmingham, Alabama • Hoover, Alabama • Hueytown, Alabama + 255 more
Completed Phase 3 Interventional Results available

Uric Acid and Hypertension in African Americans

NCT00241839
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions
Allopurinol, Placebo, Chlorthalidone, Potassium chloride
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Heart Failure, Elevated Serum Uric Acid
Interventions
allopurinol, sugar pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 6 more
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Conditions
Non Hodgkin Lymphoma
Interventions
Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

NCT02888054
Conditions
Healthy
Interventions
lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Conditions
Diabetes Mellitus, Type 2, Hyperuricemia
Interventions
Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
Mycophenolate Mofetil, Allopurinol, Irinotecan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Gout, Hyperuricemia
Interventions
dotinurad, dotinurad + allopurinol, allopurinol
Drug
Lead sponsor
Urica Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

NCT01320722
Conditions
Renal Function, Endothelial Function, Blood Pressure, Overweight, Obesity
Interventions
Vitamin D ergocalciferol, Probenecid, Allopurinol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
Interventions
AEG35156 antisense IV infusion
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Burbank, California • Valhalla, New York • Cleveland, Ohio + 1 more
Conditions
Gout
Interventions
RDEA3170 2.5 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Anaheim, California • DeLand, Florida • South Miami, Florida + 1 more
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions
Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
Interventions
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Terminated Phase 4 Interventional Results available

Allopurinol Maintenance Study for Bipolar Disorder

NCT00732251
Conditions
Bipolar Disorder, Mania, Mixed Mania
Interventions
Allopurinol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California